Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
511 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | completed | Phase 2 | 384 | Bristol-Myers SquibbINDUSTRY | 15 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV |
| 10 |
| Feb 24, 2016 |
| clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT00526669 | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib | completed | Phase 2 | 68 | GlaxoSmithKlineINDUSTRY | 6 | Jan 29, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT01672671 | BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01004081 | Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | completed | Phase 2 | 54 | BiogenINDUSTRY | 4 | Oct 2, 2015 | clinicaltrials |
| NCT00902291 | A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 5 | Sep 14, 2015 | clinicaltrials |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects | completed | Phase 2 | 67 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 13 | Sep 2, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT02145923 | Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis | unknown | Phase 1 / Phase 2 | 16 | Burnasyan Federal Medical Biophysical CenterOTHER_GOV | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT01500720 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | completed | Phase 2 | 179 | SanofiINDUSTRY | 16 | Apr 13, 2015 | clinicaltrials |
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT01472198 | A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | completed | Phase 2 | 250 | Gilead SciencesINDUSTRY | 2 | Mar 10, 2015 | clinicaltrials |
| NCT00865709 | Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects | completed | Phase 2 | 198 | BayerINDUSTRY | 10 | Dec 11, 2014 | clinicaltrials |
| NCT02004093 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 149 | Hoffmann-La RocheINDUSTRY | 9 | Dec 4, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 96 | BayerINDUSTRY | 6 | Oct 31, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT01196052 | A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 8 | Oct 6, 2014 | clinicaltrials |
| NCT00700180 | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 2 | 303 | Hoffmann-La RocheINDUSTRY | 16 | Sep 25, 2014 | clinicaltrials |
| NCT00475670 | A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 15 | Sep 15, 2014 | clinicaltrials |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | completed | Phase 2 | 271 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 8 | Sep 8, 2014 | clinicaltrials |
| NCT00125034 | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)(OPUS) | completed | Phase 2 | 344 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 13 | Aug 7, 2014 | clinicaltrials |
| NCT01151215 | Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer(MINT) | terminated | Phase 2 | 482 | AstraZenecaINDUSTRY | 18 | Jul 25, 2014 | clinicaltrials |
| NCT00373204 | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | terminated | Phase 2 | 50 | Pharmacyclics LLC.INDUSTRY | 4 | Jul 24, 2014 | clinicaltrials |
| NCT00356811 | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | completed | Phase 2 | 57 | GlaxoSmithKlineINDUSTRY | 4 | Jul 21, 2014 | clinicaltrials |
| NCT00165880 | An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine | terminated | Phase 2 | 62 | Eisai LimitedINDUSTRY | 5 | Jul 1, 2014 | clinicaltrials |
| NCT01208194 | Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma(IMPACT) | completed | Phase 2 | 59 | Mologen AGINDUSTRY | 6 | Jun 20, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT01362400 | A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 226 | Infinity Pharmaceuticals, Inc.INDUSTRY | 6 | May 19, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT00786838 | A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | completed | Phase 2 | 76 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 7 | Apr 11, 2014 | clinicaltrials |
| NCT00112060 | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Mar 31, 2014 | clinicaltrials |
| NCT01543451 | Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea | completed | Phase 2 | 138 | Helsinn Healthcare SAINDUSTRY | 4 | Mar 26, 2014 | clinicaltrials |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | terminated | Phase 2 | 30 | Janssen-Cilag International NVINDUSTRY | 7 | Mar 21, 2014 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials